Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status
| العنوان: | Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status |
|---|---|
| المؤلفون: | Stefan Ries, Ulrich Engelmann, Jennifer S Kullmann, Boris Kallmann, Laura M Quint, Andrew T. Chan |
| المصدر: | Kallmann, Boris A; Ries, Stefan; Kullmann, Jennifer S; Quint, Laura M; Engelmann, Ulrich; Chan, Andrew (2021). Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status. Therapeutic advances in neurological disorders, 14, p. 17562864211005588. Sage 10.1177/17562864211005588 <http://dx.doi.org/10.1177/17562864211005588> Therapeutic Advances in Neurological Disorders, Vol 14 (2021) Therapeutic Advances in Neurological Disorders |
| بيانات النشر: | Sage, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Pre treatment, medicine.medical_specialty, 610 Medicine & health, multiple sclerosis, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Teriflunomide, medicine, observational, RC346-429, Original Research, Pharmacology, immunosenescence, treatment, business.industry, Multiple sclerosis, satisfaction, Immunosenescence, medicine.disease, pre-treatment, switch, 030104 developmental biology, Neurology, chemistry, Relapsing remitting, age, Observational study, Neurology (clinical), Neurology. Diseases of the nervous system, Once daily, business, 030217 neurology & neurosurgery |
| الوصف: | Background and aims: To investigate effectiveness and safety of teriflunomide (14 mg once daily) in association with age and pre-treatment in unselected MS patients. Methods: Prespecified analysis of a non-interventional, prospective, real-world study in Germany. Results: A total of 558 (49.5%) patients were above 45 years old, and 593 patients (52.6%) had been pre-treated within 6 months prior to teriflunomide. Baseline Expanded Disability Status Scale (EDSS) was higher with older age, with lower number of relapses. Relapse rate decreased in all age groups, and in both treatment-naïve (0.82 ± 0.73 at baseline; 0.25 ± 0.55 under teriflunomide) and pre-treated (from 0.48 ± 0.76; 0.22 ± 0.50) patients after 12 months compared with the year before teriflunomide initiation. EDSS remained stable in patients of all age groups as well as in therapy-naïve and pre-treated patients over 24 months. The percentage of patients with adverse events (AEs) ranged between 29.2% (age group >25–35) and 38.9% (age group >55–65), with an increased discontinuation rate (most commonly due to diarrhoea, alopecia and nausea) in the higher age groups. AE rates were lower in pre-treated compared with treatment-naïve patients. Conclusion: Overall, patients of all age groups including older patients, and irrespective of pre-treatment, benefit from teriflunomide treatment in routine clinical practice. Registration: BfArM public study database number 2075. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75354bdb730ef84846d2d7012b1034a2 https://boris.unibe.ch/157488/1/Kallmann__2021__Teriflunomide_in_relapsing_remitting_MS.pdf |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....75354bdb730ef84846d2d7012b1034a2 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |